Oncology & Cancer

Researchers from the Francis Crick Institute, UCL, Gustave Roussy and Memorial Sloan Kettering Cancer Center (MSK), have discovered that expansion of mutant blood cells, a phenomenon linked to aging, can be found in cancerous tumors, and this is associated with worse outcomes for patients.

From 2000 to 2021, there was an increase in the incidence of pancreatic adenocarcinoma, which was seen in all age groups, according to a study published online April 14 in JAMA Network Open.

An interdisciplinary research team has unveiled the world’s first artificial intelligence (AI) model designed to classify both the cancer stage and risk category of thyroid cancer, achieving impressive accuracy exceeding 90%.

Overall cancer mortality rates declined from 2001 through 2022, while cancer incidence rates decreased from 2001 through 2013 and stabilized through 2021, according to the 2024 Annual Report to the Nation on the Status of Cancer published online April 21 in Cancer.

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to experience long-term disease control, according to findings published in Clinical Cancer Research.

A team of researchers from the University of Chicago, in collaboration with researchers from the University of Pittsburgh, has identified a novel oncometabolite that accumulates in tumors and impairs immune cells’ ability to fight cancer.

A new technique to mark peripheral pulmonary lesions (PPLs) before surgical resection was studied by Ganesh Krishna, M.D., a pulmonary/critical care medicine specialist, researcher and interventional pulmonologist at Sutter’s Palo Alto Medical Foundation (PAMF). Dr. Krishna is also Director of Interventional Pulmonology at El Camino Hospital in Mountain View, CA.

Somewhere in the body of a patient, a small clump of cells, growing undetected, has begun to form a tumor. It has yet to cause pain or visible symptoms of illness. Several months from now, or perhaps years, those first signs will prompt a doctor’s inquiry, a referral to a specialist, and an eventual diagnosis. Treatment will depend on how long the cancer has gone unnoticed and how far it has spread.

Physicians classify brain tumors and determine treatment options, in part, by the genes they express. According to World Health Organization standards, the abnormal activation of oncogene FOXR2 only occurs in central nervous system (CNS) neuroblastoma, but that may not be true. Findings from St. Jude Children’s Research Hospital show FOXR2 activation in multiple pediatric CNS tumor types, mostly brain tumors, with significantly different clinical outcomes.

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.